ZNTL

Zentalis Pharmaceuticals, Inc.

Fundamental data last updated:November 14, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

 


Analyze ZNTL on TradingView

VALUATION

P/E

-0.72

Market Cap ($M USD)

$125.96M

Forward P/E

108.68

PEG

-0.05

PRICE TO SALES

0.00

PRICE TO BOOK

0.87

EV / EBITDA

-0.80

5-Year Average P/E

Free Cash Flow Yield

-127.92%

DCF Value

$-0.12

Graham Number

N/A

Price to FCF

-0.78

EV to FCF

-0.86

Earnings Yield

-140.68%

FCF Yield

-127.92%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.49

Next Year EPS Growth Estimate

-$2.09

Next Year Revenue Growth Estimate

$2.14M

Return on Equity (ROE)

-87.95%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.26

Piotroski F-Score

2

Altman Z-Score

-9.09

Return on Invested Capital (ROIC)

-105.17%

Current Ratio

4.82

Quick Ratio

4.82

Net Debt to EBITDA

-0.07

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-2.29

REVENUE PER SHARE

$0.00

Analyze ZNTL on TradingView

Gainseekers Quantitative Analysis

Summary

Zentalis Pharmaceuticals, Inc. is a perplexing case of financial extremes. The market’s valuation seems disconnected from its fundamentals, with a Forward P/E of 108.68 suggesting high growth expectations, yet the Altman Z-score of -8.95 signals distress. The negative Earnings Yield and DCF Value further highlight a company struggling to justify its current pricing. Despite a Price/Book ratio below 1, which might suggest undervaluation, the overall financial health is precarious, raising red flags for potential investors.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Zentalis is inherently positioned to leverage AI advancements in drug discovery and development. The industry's rapid adoption of technology could enhance its research capabilities. However, the company's current financial metrics suggest it may struggle to capitalize on these opportunities effectively.

The Bull Case

For the optimistic investor, Zentalis offers a speculative play on potential turnaround. The low Debt/Equity ratio of 0.26 indicates manageable leverage, while the high Current Ratio of 4.82 suggests liquidity strength. Despite a dismal Piotroski F-Score of 2, the company's ability to potentially harness its cash reserves for strategic pivots could appeal to those betting on a biotech resurgence.

The Bear Case

The bear case for Zentalis is glaringly evident in its financial metrics. With a Return on Equity of -87.95% and a ROIC of -105.17%, the company is hemorrhaging value. The negative FCF Yield and Price to FCF ratio underscore a dire cash flow situation. Additionally, the stock's technical position, extended 254.59% from its 52-week high, suggests it's overbought and vulnerable to correction.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$7.67

Institutional Ownership %

1-Year Beta

1.93

Insider Buying % (6 Mo)

Distance to 52-Week High

292.79%

Distance to 52-Week Low

29.35%

EARNINGS SURPRISE %

-20.41%

50-DAY SMA

$2.74

200-DAY SMA

$3.42

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.